Traduction de «patients with peripheral arterial disease » (Français → Néerlandais) :

Cacoub PP, Bhatt DL, Steg PG, Topol EJ, Creager MA. Patients with peripheral arterial disease in the CHARISMA trial.
Warfarin Antiplatelet Vascular Evaluation Trial Investigators, Anand S, Yusuf S et al. Oral anticoagulant and antiplatelet tjerapy and peripheral arterial disease.

Hirsch AT, Haskal ZJ, Hertzer NR et al. ACC/AHA 2005 Guidelines for the management of patients with peripheral arterial disease (lower extremity, renal, mesenteric and abdominal aortic): Executive summary.
2011: Rooke TW, Hirsch AT, Misra S et al. 2011 ACCF/AHA Focused update of the guideline for the management of patients with peripheral artery disease.

Update 2011: Rooke TW, Hirsch AT, Misra S et al. 2011 ACCF/AHA Focused update of the guideline for the management of patients with peripheral artery disease.
Scottish Intercollegiate Guidelines Network. Diagnosis and management of peripheral arterial disease.

Cilostazol, naftidrofuryl oxalate, pentoxifylline and inositol nicotinate for the treatment of intermittent claudication in people with peripheral arterial disease.
Salhiyyah K, Senanayake E, Abdel-Hadi M et al. Pentoxfylline for intermittent claudication.

Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomised, double-bl Lancet 362 : 782-788(2003)
Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomised, double-bli Lancet 362 : 782-788(2003)

J. Hypertension 21, 1771- 1773 (2003) The EURopean trial On reduction of cardiac events with Perindopril in stable coronary Artery disease Investigators.
J. Hypertension 21, 1771-1773 (2003) The EURopean trial On reduction of cardiac events with Perindopril in stable coronary Artery disease Investigators.

Dans l’étude POPADAD (Prevention of Progression of Arterial Disease and Diabetes Study Group), une étude randomisée contrôlée en double aveugle, ayant inclus des patients diabétiques de type 2 présentant une artériopathie périphérique asymptomatique- et sans affection cardio-vasculaire symptomatique- l’administration d’acide acétylsalicylique (100 mg p.j) et/ou d’antioxydants n’a pas diminué le risque cardio-vasculaire, ni la mortalité après un suivi moyen d’environ 6,5 ans [ Brit Med J 2008; 337: a1840 avec éditorial : a1806 ].
In de POPADAD-studie (Prevention of Progression of Arterial Disease and Diabetes Study Group), een gerandomiseerde gecontroleerde dubbelblinde studie bij patiënten met type 2-diabetes met asymptomatische perifere arteriopathie – en zonder symptomatische cardiovasculaire aandoening – werd met acetylsalicylzuur (100 mg p.d) en/of anti-oxidantia, na een gemiddelde follow-up van ongeveer 6,5 jaar, geen daling van het cardiovasculaire risico of van de mortaliteit gezien [ Brit Med J 2008; 337: a1840 met editoriaal : a1806 ].

Search Date July 2007. [http ...]
Kaltenbach T, Crockett S, Gerson L. Are lifestyle measures effective in patients with gastroesophagal reflux disease?

Maron DJ. Review: statins do not reduce mortality in patients with no history of cardiovascular disease.
Bespreking van: Ray KK, Seshasai SRK, Erqou S et al. Statins and all-cause mortality in high-risk primary prevention.

of major cardiovascular events in patients with chronic obstructive pulmonary disease: a systematic review and meta-analysis.
Inhaled anticholinergics and risk of major cardiovascular events in patients with chronic obstructive pulmonary disease: a systematic review and meta-analysis.